Pacific Biosciences (NASDAQ:PACB) just reported results for the first quarter of 2024.
- Pacific Biosciences reported earnings per share of -26 cents. This was above the analyst estimate for EPS of -27 cents.
- The company reported revenue of $38.81 million.
- This was 9.66% worse than the analyst estimate for revenue of $42.96 million.